Oncology Medical News about hematological malignancy;HDAC inhibitor-based therapies

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

HDAC inhibitor-based therapies and haematological malignancy
Annals of Oncology, 06/12/09

Stimson L et al. - In a review of histone deacetylase (HDAC) inhibitor-based therapies and haematological malignancy, this article discusses developments in the understanding of molecular events that underlie the anticancer effects of HDAC inhibitors and relates this information to the emerging clinical picture for the application of HDAC inhibitors in haematological malignancies.

Methods

Reversible acetylation mediated by HDAC influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumour cells.
Since HDAC inhibition prompts tumour cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new class of mechanism-based anticancer agent, many of which have entered clinical trials.

Results

While the clinical picture is evolving and precise utility of HDAC inhibitors remains to be determined, it is noteworthy that certain tumour types undergo a favourable response, in particular haematological malignancies.
Vorinostat (suberoylanilide hydroxamic acid) has been approved for treating cutaneous T-cell lymphoma in pts with progressive, persistent or recurrent disease.

<< Previous
Favorable impact of the interleukin-4 receptor allelic variant...

Next >>
Synchronous colorectal liver metastases: is it time to reconsider...